1. Home
  2. OGN

as of 02-10-2026 3:46pm EST

$7.88
$0.04
-0.44%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Founded: 1923 Country:
United States
United States
Employees: N/A City: JERSEY CITY
Market Cap: 1.8B IPO Year: N/A
Target Price: $14.10 AVG Volume (30 days): 6.2M
Analyst Decision: Hold Number of Analysts: 5
Dividend Yield:
1.01%
Dividend Payout Frequency: Quarterly
EPS: 1.91 EPS Growth: -62.07
52 Week Low/High: $6.18 - $17.23 Next Earning Date: 02-12-2026
Revenue: $6,301,000,000 Revenue Growth: -1.69%
Revenue Growth (this year): -1.75% Revenue Growth (next year): -1.73%
P/E Ratio: 4.14 Index: N/A
Free Cash Flow: 777.0M FCF Growth: +4.02%

AI-Powered OGN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 76.62%
76.62%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Organon & Co. News

OGN Breaking Stock News: Dive into OGN Ticker-Specific Updates for Smart Investing

All OGN News

Share on Social Networks: